Download presentation
Presentation is loading. Please wait.
Published byViviane Sergerie Modified over 6 years ago
1
Once-Daily Opioids for Chronic Dyspnea: A Dose Increment and Pharmacovigilance Study
David C. Currow, BMed, MPH, FRACP, Christine McDonald, MBBS, PhD, FRACP, Sheila Oaten, RN, Bernadette Kenny, BEc, RN, Peter Allcroft, BMBS, FRACP, Peter Frith, MBBS, PhD, FRACP, Michael Briffa, BMBS, FRACGP, FAChPM, Miriam J. Johnson, MB ChB, MD, FRCP, MRCGP, Amy P. Abernethy, MD Journal of Pain and Symptom Management Volume 42, Issue 3, Pages (September 2011) DOI: /j.jpainsymman Copyright © 2011 U.S. Cancer Pain Relief Committee Terms and Conditions
2
Fig. 1 Schema for participant flow in a Phase II and Phase IV open-label dose-ranging study of once-daily sustained-release morphine in people with refractory dyspnea. Journal of Pain and Symptom Management , DOI: ( /j.jpainsymman ) Copyright © 2011 U.S. Cancer Pain Relief Committee Terms and Conditions
3
Fig. 2 Participant flow diagram for Phase II dose ranging and Phase IV continued clinical effectiveness study for once-daily sustained-release morphine in refractory dyspnea. Journal of Pain and Symptom Management , DOI: ( /j.jpainsymman ) Copyright © 2011 U.S. Cancer Pain Relief Committee Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.